• Swallow the tablet whole with a glass of water.
• Do not crush, chew, or break the tablet.
• It is recommended to take this medication with your first main meal of the day.
• Always follow your doctor's instructions on how to use this medicine.
Glynux MP 1 Tablet is primarily utilised to manage type 2 diabetes mellitus, characterised by elevated blood glucose levels due to insulin resistance or deficiency. It belongs to a class of combination medications including sulfonylureas, biguanides, and thiazolidinediones.
Glynux MP 1 Tablet is indicated for:
• Improving blood sugar control in adults with type 2 diabetes
• Managing type 2 diabetes when diet and exercise are insufficient
• Enhancing glycaemic control in patients not adequately controlled by individual components of the medication
• Swallow the tablet whole with a glass of water.
• Do not crush, chew, or break the tablet.
• It is recommended to take this medication with your first main meal of the day.
• Always follow your doctor's instructions on how to use this medicine.
Glynux MP 1 Tablet is taken orally.
Glynux MP 1 Tablet may cause the following common side effects:
• Hypoglycaemia
• Oedema
• Nausea
• Vomiting
• Diarrhoea
• Abdominal pain
• Headache
Glynux MP 1 Tablet contains three active agents:
• Glimepiride (1 mg): A sulfonylurea that stimulates insulin secretion from pancreatic beta cells by interacting with surface receptors, facilitating calcium influx and insulin release.
• Metformin (500 mg): As a biguanide, metformin decreases hepatic glucose production by inhibiting gluconeogenesis and glycogenolysis and enhances peripheral insulin sensitivity and intestinal glucose absorption.
• Pioglitazone (15 mg): A thiazolidinedione that augments insulin sensitivity in muscle and adipose tissue and decreases hepatic glucose output by activating PPAR-γ, a nuclear receptor involved in glucose and lipid metabolism.
Glynux MP 1 Tablet is not recommended during pregnancy. If you are pregnant, consult your doctor for alternative options.
This medication should not be taken while breastfeeding. Consult your doctor before use.
Consuming alcohol increases the risk of hypoglycaemia. Limit or avoid alcohol intake while using this medicine.
Caution is advised in patients with liver dysfunction. Consult your doctor if you have any liver conditions.
Avoid use in severe kidney impairment. Consult your doctor for dosage adjustments if you have mild to moderate kidney issues.
The medicine may induce hypoglycaemia, leading to dizziness or reduced alertness. Avoid operating machinery or driving if you experience these symptoms.
If you have an allergy to glimepiride, metformin, pioglitazone, or any excipients, avoid using this medication. Inform your doctor of any allergies.
Not recommended for individuals under 18 years. Consult your doctor for paediatric options.
Utilise under medical supervision due to increased susceptibility to side effects, particularly concerning kidney function.
Drug-Drug Interactions
• Enzyme Inducers: Medications that induce CYP2C8 may decrease the efficacy of pioglitazone.
• Glucose Metabolism Affecting Agents: Corticosteroids, thiazides, and thyroid products may alter glucose control. Additional monitoring might be necessary.
Daily Dosage
• Glynux MP 1 Tablet should be taken as advised by your doctor.
Missed Dose
• If you miss a dose, take it as soon as you remember. If it is nearly time for your next dose, skip the missed dose. Do not double the dose to catch up.
Overdose
• Symptoms of overdose may include dizziness, nausea, and diarrhoea. Seek medical attention if an overdose is suspected.
• Store at a temperature not exceeding 30°C.
• Protect from light and moisture.
• Keep out of reach of children.
• Use before the expiration date.
• Engage in regular physical activity, aiming for at least 30 minutes of moderate exercise daily.
• Incorporate a diet rich in whole grains, lean proteins, fruits, and vegetables.
• Limit intake of sugary and fatty foods.